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Zheng et al. report that variable mutation
densities within cancer genomes result
from differential access of DNA repair ma-
chinery, imposed by chromatin state. By
showing that transcription restores DNA
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expression level as a potentially impor-
tant modulator of oncogene mutation
rate.
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SUMMARY
Somatic mutations in cancer are more frequent in
heterochromatic and late-replicating regions of the
genome. We report that regional disparities in muta-
tion density are virtually abolished within transcrip-
tionally silent genomic regions of cutaneous squa-
mous cell carcinomas (cSCCs) arising in an XPC/
background. XPC/ cells lack global genome
nucleotide excision repair (GG-NER), thus establish-
ing differential access of DNA repair machinery
within chromatin-rich regions of the genome as the
primary cause for the regional disparity. Strikingly,
we find that increasing levels of transcription reduce
mutation prevalence on both strands of gene bodies
embedded within H3K9me3-dense regions, and only
to those levels observed in H3K9me3-sparse re-
gions, also in an XPC-dependent manner. Therefore,
transcription appears to reduce mutation prevalence
specifically by relieving the constraints imposed by
chromatin structure on DNA repair. We model this
relationship among transcription, chromatin state,
and DNA repair, revealing a new, personalized deter-
minant of cancer risk.
INTRODUCTION
Somatic point mutations and chromosomal aberrations in can-
cer are not distributed uniformly throughout the genome (Alexan-
drov et al., 2013; Ja¨ger et al., 2013; Lawrence et al., 2013; Polak
et al., 2014). Despite the myriad mutational processes active in
human cancers (Alexandrov et al., 2013), similar regional pat-
terns of somaticmutation density are observed acrossmanyma-
lignancy types, suggesting a common underlying mechanism
(Hodgkinson et al., 2012; Lawrence et al., 2013). Chromatin or-
ganization heavily influences regional mutation rate, with higher
densities of mutation observed in tightly packaged DNA, corre-
sponding to late-replicating portions of the genome and genes
with lower expression level (Liu et al., 2013; Schuster-Bo¨ckler
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and Lehner, 2012). For example, more than 40% of mutation
frequency variation is correlated with the heterochromatin-asso-
ciated histone modification H3K9me3 in both solid and hemato-
logic cancer types (Schuster-Bo¨ckler and Lehner, 2012).
The reason why chromatin density and replication timing pre-
dict regional heterogeneity inmutationprevalence is unclear.Mu-
tation rate correlatesmost stronglywithH3K9me3 and to a lesser
degree with H4K20me3 and H3K79me3 (Schuster-Bo¨ckler and
Lehner, 2012). All threemarks correlatewith constitutively closed
chromatin states, cytogenetically recognizedasheterochromatin
(Barski et al., 2007; Mikkelsen et al., 2007), suggesting a specific
chromatin conformation may underlie the variance. Higher tran-
scription rates correlate with lower prevalence of mutations orig-
inating on transcribed strands of genes (Pleasance et al., 2010),
but transcription-coupled nucleotide excision repair (TC-NER)
explains only a fraction of observed regional heterogeneity. It
has been speculated that late-replicating regions suffer from
lower-fidelity DNA synthesis because of depletion of the free
nucleotide pool (Liu et al., 2013; Stamatoyannopoulos et al.,
2009). However, a direct functional effect of specific chromatin
state or replication timing on NER has not been established in
humans (Gospodinov and Herceg, 2013). Recently, some mela-
nomas with acquired mutations in NER genes were shown to
demonstrate weaker association of mutation density with tran-
scription and DNase I hypersensitivity sites (Polak et al., 2014).
RESULTS
We sought to understand whether observed differences in
regional mutation frequency within cancer genomes were driven
primarily by NER activity. We studied tumors from patients with
xeroderma pigmentosum (XP), a spectrum of genetic disorders
associated with defects in NER (Cleaver, 2005). Patients with
loss of function in XPC are defective in global genome nucleotide
excision repair (GG-NER) but proficient in TC-NER. If regional
mutation frequency were caused by NER, in an XPC/ back-
ground, we would expect regional disparities in mutation to
persist within transcriptionally active portions of the genome,
but not within transcriptionally silent regions. To test this hypoth-
esis, whole-genome sequences were obtained from cSCCs
arising in five patients with homozygous frameshift mutations
(C940del-1) in the XPC gene (Cleaver et al., 2007), as well as
from eight patients with no known major germline DNA repair
deficiency (repair wild-type [WT]) (Table S1) (Durinck et al.,
2011). A total of 3,543,126 point mutations were identified. As
expected for skin cancers, transitions (C > T/G > A) typical of
UV damage predominated among detected mutations, repre-
senting 76% of point mutations in WT cutaneous squamous
cell carcinomas (cSCCs) and 86% in XPC/ cSCCs. Mutation
frequency, measured as transition mutations per kilobase, was
explored in relation to chromatin structure, replication time,
and gene expression using ENCODE data derived from keratino-
cytes (ENCODE Project Consortium, 2012).
Regional Mutation Disparities in Cancer Genomes
Result Primarily from DNA Repair
Consistent with recent work (Liu et al., 2013; Schuster-Bo¨ckler
and Lehner, 2012), we report thatmutation prevalence correlated
directly with both H3K9me3 density (p < 0.001) and replication
time (p < 0.001), and anticorrelated with density of the repressive
mark H3K27me3, within both expressed and nonexpressed por-
tions ofWT cancer genomes (Figure 1). Strikingly, in all five exam-
inedXPC/ cancers, these associationswere virtually abolished
in nonexpressed portions of the genome, with mutation density
at most 10% of that of WT cancers (Figure 1) and reduced
to about half of that of WT cancers in expressed portions of
the genome, where only TC-NER would be expected to remain
active. Increased mutation density was also associated with
sparser active histone marks such as H3K27ac and H3K4me1,
and these relationships were once again absent within nonex-
pressed regions of XPC/ cancers (Figure S1).
In WT cSCC genomic regions with the lowest H3K9me3 den-
sity and highest transcription levels, our measure of TC-NER
(the reduction of mutation density resulting from lesions on the
transcribed strand, as a proportion of all expected mutations)
was 29%–34% (Table S2). Interestingly, in regions with the
highest H3K9me3 density and highest transcription levels, this
reduction was only 16%–25%, suggesting that exclusion of
TC-NER machinery within tightly packaged DNA may decrease
its activity. In WT cancers, differences in TC-NER comprised
on average only 1.4% of differences between the highest and
lowest H3K9me3 densities, at the 70th percentile of most highly
expressed genome (Table S3). In contrast, in XPC/ cancers,
44% of the differences in mutation prevalence between the high-
est and lowest H3K9me3 levels could be ascribed to differences
in TC-NER. Because TC-NER is not affected by loss of function in
XPC, it is expected that TC-NER would be responsible for a
greater proportion of residual disparities in mutation density in
XPC/ cancers (van Hoffen et al., 1995). Collectively, these find-
ings reveal that the primary cause of regional disparities in muta-
tion prevalence is differential access of DNA repair proteins
imposedbychromatin state, specificallyNER in cSCCs.Because
global patternsofH3K9me3density correlatewithmutation prev-
alence across many different cancer types (Polak et al., 2014;
Schuster-Bo¨ckler and Lehner, 2012), it is possible that thismech-
anism is active in other neoplasms and forms of mutagenesis.
Transcription Enhances DNA Repair Only in Chromatin-
Dense Portions of the Genome
We further analyzed the quantitative effects of GG-NER and
TC-NER on mutation density in cancer genomes. In WT cSCCs,
regions with greater expression levels showed a significantly
decreased density of mutation originating both on the tran-
scribed and untranscribed strands. The magnitude of this effect
increased with greater H3K9me3 density and replication time
(Figures 2 and S2). Notably, in XPC/ cancers, higher expres-
sion levels only reduced the frequency of mutations resulting
from lesions on the transcribed strand, an effect that can be
attributed to TC-NER. However, the transcription-dependent
(but TC-NER-independent) DNA repair observed on the untran-
scribed strand of WT cSCCs is possibly identical to an XPC-
dependent phenomenon termed transcription domain-associ-
ated repair (DAR) (Nouspikel and Hanawalt, 2000; Nouspikel
et al., 2006), which affects both strands in expressed regions.
Although DAR is active on both strands of expressed
genes, a representative measure of DAR activity is limited to
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the untranscribed strand where TC-NER is absent. In the WT
cSCC genome, the impact of DAR, measured as decreasing
mutation frequency from lesions on the untranscribed strand
with increasing expression, was substantial. For example, within
nonexpressed portions of WT cSCC genomes (RPKM [reads as-
signed per kilobase of target per million mapped reads] < 0.01),
mutation frequencies in regions with high H3K9me3 levels were
approximately 3-fold greater than those with low H3K9me3
levels, consistent with recent estimates (Lawrence et al., 2013).
In contrast, for highly expressed genes (e.g., RPKM = 400), this
difference disappeared, with frequency of mutations originating
on the untranscribed strand of all regions approaching that of
DNA with low chromatin levels (gray dashed line at H3K9me3 =
1; Figure 2). This effect was also seen in three WT basal cell car-
cinomas (Figures 3F–3H). However, expression levels showed
no effect on mutation frequencies in genomic regions with the
lowest H3K9me3 levels.
Proto-Oncogene Transcription Level Significantly
Influences Mutation Frequency
We noted that the differences in mutation frequency associated
with both transcription and chromatin state were of comparable
magnitude to those caused by XPC loss of function. On average,
XPC/ tumors harbor about a 5-fold greater mutation burden
compared to WT cancers in transcribed regions (Table S4), illus-
trating howmodest differences in mutation frequency can confer
a large increase in cancer susceptibility. For reference, if five to
six independent mutations were required for cSCC formation,
a 5-fold increase in frequency of each mutation would raise the
cancer rate by about 4,000-fold, approximately the observed in-
crease in XPC patients (DiGiovanna and Kraemer, 2012; Leh-
mann et al., 2011). For genes in regions of the greatest
H3K9me3 density in WT cancers, overall mutation density was
lowered up to 4.7-fold as a result of higher expression, resulting
from combined activities of GG-NER (in the form of DAR) and
Figure 1. Regional Disparities in Mutation Density Are Absent in Nonexpressed Portions of the Genome of Germline XPC/ Squamous Cell
Carcinomas
The x axis of each graph shows increasing ChIP intensity of the heterochromatin-associated histone mark H3K9me3 (ENCODE data, Broad Institute) (A and C)
and increasing inverse median RepliSeq values representing later replication time (ENCODE data, University of Washington) (B and D). The y axis represents the
mutation density per kb divided by the individual mean. Plotted are values for either eight aggregated repair wild-type (WT) cancers (solid blue line) or five
aggregated XPC/ cancers (broken orange line) for 8 equally sized genomic bins covering approximately 2Gb of expressed genome and 1Gb of nonexpressed
genome (±SD). Whereas mutation density correlates positively with increasing H3K9me3 and later replication time for expressed regions in repair WT cancers,
these associations are diminished in XPC/ samples (A and B). In nonexpressed portions of the genome, regional disparities in mutation density are almost
completely abolished in XPC/ samples (C and D), indicating loss in the absence of GG-NER. See Figure S1 for additional data with sparser active marks
H3K27ac and H3K4me1 and Table S1 for additional information on tumor samples.
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TC-NER (Table S5). Furthermore, in WT tumors, we found a 3- to
4-fold reduction in mutation prevalence resulting from TC-NER
of lesions on the transcribed strand (this reduction is 30-fold in
XPC/ tumors, possibly as the result of TC-NER acting in a
compensatory role) (Table S6).
These observations led us to explore the possibility that natu-
ral variation in mRNA expression levels could exert an important
influence on the mutation frequency of oncogenes located in
tightly packaged DNA. In expression data obtained from the Ge-
notype-Tissue Expression database (GTEx Consortium, 2013),
we found that 72% of genes expressed in skin samples showed
a 2-fold or greater variation in expression within a group of about
150 individuals. Similarly within660 lymphocytic cell lines in the
1000 Genomes Project (Lappalainen et al., 2013), 80% of
genes demonstrated at least a 2-fold difference. Thus, we as-
sessed the potential impact of a 2-fold expression variance in
our model. First, the variable ɵ was modeled: the fold increase
in mutation frequency resulting from a 50% decrease in expres-
sion level, for a given H3K9me3 level, based on our data in WT
cSCCs (Supplemental Experimental Procedures). We then
examined ɵ for 261 genes recently identified in a meta-analysis
as recurrently mutated in human cancers (Lawrence et al.,
2013). Genes were divided into 20,841 1 kb genomic segments
for analysis (Figure 3; Table S7).
Our estimates of ɵ predict that a 50% reduction in expression
level would increase mutation frequency by 10%–20% or more
for multiple exons in the SCC tumor suppressor genes TP53,
NOTCH1, and IRF6 (Agrawal et al., 2011; Wang et al., 2011).
The exon with the highest ɵ in this set, 1.21, belongs to
CDC27, a gene demonstrating a 2% mutation frequency in
head and neck SCCs and 4% in melanomas (Cerami et al.,
2012), cancers whose tissues of origin depend on NER to control
mutation frequency. The clinical impact of such effects in a pop-
ulation could be evaluated by determining both gene mutation
Figure 2. Domain-Associated Repair Restores Low Mutation Rate Only to Highly Transcribed Genes in Tightly Packaged DNA
The x axis denotes increasing expression in NHEK, measured in RPKM (plotted on a log scale). On the y axis is the mutation density per kb. Values are plotted for
three independent WT cSCCs (A–C) and three independent XPC/ cSCCs (D–F). The plots show six different H3K9me3 densities representing different
chromatin levels, represented by distinct colors, for the transcribed (solid line) and untranscribed (broken line) strands. The shaded area behind each line
represents 95% confidence bands of the plotted line. In WT cancers, both strands show decreasing mutation density in tightly packaged DNA, illustrating robust
domain-associated repair (DAR). DAR restoresmutation rate in themost heterochromatic genomic regions to that of euchromatic regions, evidencing a dominant
effect over chromatin state, but negligible additional impact in euchromatin (low H3K9me3). Even lower mutation density is seen from lesions on the transcribed
strand, presumably representing TC-NER. In contrast, the XPC/ cancers show an absence of DAR, represented by an absence of transcription-dependent
repair on the untranscribed strand, but intact TC-NER. See Figure S2 for additional samples and Tables S2, S3, S4, S5, S6 for more detailed mutation density
information.
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density and expression level in a large series of tumors. We es-
timate that to have an 80% chance of detecting a 15% increase
in mutation density in a gene within highly mutated cancers such
as ours, a study would need to be powered with a minimum of
approximately 600 samples at each transcript level (Supple-
mental Experimental Procedures).
DISCUSSION
Our data show that in the germline absence of GG-NER, regional
disparities in mutation density associated with chromatin-dense
regions are virtually abolished in nonexpressed portions of can-
cer genomes, while the residual differences in mutation preva-
lence within expressed portions of the genome predominantly
arise from disparities in TC-NER. Therefore, we establish that
DNA repair efficiency is the main source of regional disparities
in mutation density in cSCCs.
Unexpectedly, we also find that transcription and chromatin
state do not influence mutation density independently. The
decrease in mutation prevalence resulting from increasing levels
of transcription was found to be correlated with H3K9me3 den-
sity and is in fact absent at the lowest H3K9me3 levels. A parsi-
monious interpretation of these data is that DAR acts solely and
dominantly to restore GG-NER to expressed areas within tightly
packaged DNA, perhaps as a result of transcriptional complexes
increasing DNA accessibility to damage sensors such as XPC,
rather than by a directed process such as TC-NER. This hypoth-
esis agrees with previous observations that DAR proceeds even
in the presence of RNA polymerase II inhibitors (Nouspikel et al.,
Figure 3. Gene Expression Significantly
Alters Tumor Suppressor Mutation Rates
The x axis shows increasing H3K9me3 intensity,
representing a more repressive chromatin state.
The y axis shows the fold increase of the proba-
bility of a mutation, given a 50% decrease in
expression level, referred to here as ɵ. Plotted is ɵ
for 20,841 1 kb segments covering transcribed
portions of 261 genes recently identified as
recurrently mutated in human cancers. High-
lighted are 1 kb fragments containing exons for the
SCC tumor suppressors TP53 (A), NOTCH1 (B),
and IRF6 (C), as well as for the gene with exons of
greatest average level of such mutation variance,
CDC27 (D), which has been shown to be mutated
at about 4% in melanomas and 2% in head and
neck SCCs. Exons with the highest variance and
its corresponding ɵ are indicated. See Table S7 for
ɵ for all 20,841 1 kb segments.
2006) and suggests a mechanism by
which active genes maintain lower muta-
tion frequencies, even in heterochromatic
regions with reduced access to NER
machinery. Highly expressed gene seg-
ments with greater H3K9me3 density
have these marks concentrated in gene
bodies, but not promoters. We therefore
conclude that gene expression plays a
critical role by relieving the structural
constraints imposed by densely packed chromatin on DNA
repair machinery, rather than simply influencingmutation density
alongside chromatin state either independently or in correlation.
We further establish that the natural variation in transcription
level of proto-oncogenes, between individuals, is sufficient to
significantly influence their mutation rate. Our results therefore
not only reveal a mechanistic basis for variable mutation density
within cancer genomes but also show how to estimate proto-
oncogene mutation rates of individuals in a population based
on gene expression and chromatin state. These differences
reveal an individual-specific modulator of risk for specific can-
cers, deserving further investigation in population-based studies.
EXPERIMENTAL PROCEDURES
Study Design, Tumor Samples, and DNA Sequencing
Tumor samples were obtained for five germline XPC/ cSCCs following a
UCSF Committee on Human Research protocol addressing isolation of these
tumors during surgery. At least 5 mg of DNA was collected from dissected
tissue or peripheral blood and sequenced using the Illumina HiSeq2000
systems. More than 85% of targeted regions received 70-fold coverage at
>90% of bases. Processing of raw sequencing data was performed using
BWA (Li et al., 2008), samtools (Li et al., 2009), and GATK software packages
(http://www.broadinstitute.org/gatk/). A detailed description of thesemethods
is provided in Supplemental Experimental Procedures.
Processing of NHEK Chromatin and Replication Time Data
Hg19 chromatin immunoprecipitation (ChIP) sequencing signal intensity of
H3k4me1, H3k9me3, and H3k27ac (Ram et al., 2011) and percentage-normal-
ized signal Repli-seq data (Hansen et al., 2010) were obtained from ENCODE
for normal human epidermal keratinocytes (NHEK) (ENCODE Project
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Consortium, 2012). Signal intensities were averaged for 1 kb intervals across
the genome. Genomic regions overlapping gaps (e.g., centromeres, telo-
meres) within the genomic assembly (Hg19 gap track from the UCSC Genome
Browser) were excluded.
Identification of Expressed and Nonexpressed Genomic Regions
in NHEK
Whole-NHEK-cell long poly(A) and non-poly(A) RNA fastq files generated by
CSHL were downloaded from ENCODE and aligned to Hg19 using STAR
V2.3.0.e (Dobin et al., 2013) with default parameters except for allowing for a
maximum of two mismatches. Nonexpressed genomic regions were then
identified as 1 kb regions with zero readsmapped to that region and expressed
genomic regions were identified as 1 kb regions with one ormore readmapped
to that region. Genomic regions encompassed by spliced reads (e.g., introns)
were included as expressed genomic regions. As defined by these parame-
ters, 2,065,687 1 kb regions were identified as expressed, and 1,032,437 1
kb regions were identified as nonexpressed.
Processing of NHEK Expression Data
NHEK RPKM data for Hg19 Gencode v.10 annotated genes were down-
loaded from the Encode RNA Dashboard (http://genome.crg.es/
encode_RNA_dashboard/hg19/). RPKM values were assigned to 1 kb
genomic intervals spanning the length of the entire gene, including introns.
Modeling of Mutation Density versus Genomic Feature
For each 1 kb region of the genome, the numbers of mutations were calculated
as well as the total number of ‘‘callable’’ nucleotide positions, i.e., that met the
criteria for being called mutated (at least 83 coverage for the tumor and 43
coverage for the normal). Additionally, for the 1 kb bins within annotated
gene regions (Hg19Gencode v.10), the number ofmutations on the transcribed
and untranscribed strands was counted separately. The expressed/nonex-
pressed portions of the genomewere divided into eight equal bins with respect
to increasing intensities of individual histone density signals based on ChIP
from ENCODE data. For replication timing, expressed and nonexpressed por-
tions of the genome were divided into eight equal bins based on (1/Repli-seq
intensity) 3 103. Mutations per megabase within each bin were calculated as
the total number ofmutations normalized by the total number of callable bases.
To aggregateWT and XPC/ samples, respectively, mutations per megabase
for each sample were normalized by the mean mutation rate of each sample.
Relationship of Mutation Density to Histone and Expression Levels
For analysis, we considered only regions with (1) at least 100 bp of callable
positions, (2) nonmissing RPKM and histone values, and (3) annotated genes
(Hg19 Gencode v.10). This resulted in a total of 1,160,378 1 kb regions. We
fit a generalized linear model (GLM) separately to the transcribed and untran-
scribed counts for each sample in order to estimate the proportion of bases
mutated as a function of the RPKM and histone values at a base. The proba-
bility of a mutation at a position i, denoted as pi, was modeled as a function of
its RPKM value (RPKMi) and histone value (Histonei). We used a standard GLM
model for binomial data:
log
pi
1 pi = b0 + bRPKM

logRPKMi + e





In order to work on the log scale and handle zero-valued data, RPKM values
were shifted by exp(5)z 0.006, as noted in the above equation. The input to
the model was the number of mutated positions and the total number of call-
able positions, per 1 kb region. We fit this model using the glm function in R,
allowing for overdispersion in the data via the standard quasi-likelihood option
for the binomial family. Confidence intervals for the fitted model were provided
via the predict function in R.
Relationship of Mutation Rate to Histone and Replication Time for
Nonexpressed Regions
A similar strategy was performed for calculating the relationship between his-
tone and mutation rate for nonexpressed regions. In this analysis, only regions
with at least 100 bp of callable positions and that were manually identified as
nonexpressed in the sample as described above, were included, a number
that varied per sample. The GLM model was the same as above, only without
the terms involving RPKM:
log
pi
1 pi = b0 + bHistone log Histonei :
For replication timing, the same model was used, only log Histonei was
replaced by 1=Reptimei, where Reptimei refers to Repli-seq intensity for the
region. The reported p value for the significance of histone or replication in pre-
dicting mutation rate was the p value determined by testing the null hypothesis
that bHistone = 0 or bReptime = 0, respectively.
Fold Increase in Mutation Density Resulting from 50% Decrease in
Expression
The overall mutation rate (resulting from lesions on the transcribed and untran-
scribed strands combined) was modeled as a function of histone and RPKM
on the log scale using a GLM, in the same manner as described above. Using
thismodel, we calculated the rate of change of the log-odds ofmutation rate as
a function of RPKM for a fixed level of histone. This was computed as the par-
tial derivative of the log-odds of a mutation with respect to the log of RPKM,
which simplifies to
dðlog oddsÞ= ðbRPKM + bInt logðHistoneiÞÞ dðlog RPKMÞ:
Because the probability of a mutation is very small, the log-odds are approx-
imately equivalent to the log of the mutation probability. Then for a change in
RPKM of X1 to X2, and histone levels held constant, we can approximate the







bRPKM + bInt logðHistoneÞ
:
ACCESSION NUMBERS
The sequencing data have been deposited to dbGAP under accession number
phs000830.v1.p1.
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Supplemental Information includes Supplemental Experimental Procedures,
two figures, and seven tables and can be found with this article online at
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